NEW YORK (GenomeWeb) – Rosetta Genomics announced today that it has agreed to acquire CynoGen, a molecular diagnostics laboratory doing business as PersonalizeDx, for $2 million in cash plus stock.

Through the deal, Rosetta will pick up PersonalizeDx's portfolio of proprietary fluorescence in situ hybridization-based tests for prostate, bladder, and lung cancers, as well as a CLIA lab in Lake Forest, Calif.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.